The Oncology Institute, Inc. reported significant financial results for the third quarter of 2025, with total operating revenue reaching $136.6 million, a 36.7% increase from $99.9 million in the same period of 2024. The growth was primarily driven by a 21% rise in patient services revenue, which totaled $60.2 million, and a substantial 57.4% increase in dispensary revenue, amounting to $75.9 million. However, the company experienced a net loss of $16.5 million for the quarter, slightly higher than the $16.1 million loss reported in the prior year. For the nine months ending September 30, 2025, total revenue was $360.8 million, up 23.1% from $293.1 million in 2024, while the net loss for the period was $53.1 million compared to $51.5 million in the previous year.
In terms of operational metrics, the company maintained 66 clinic locations across five states, employing 120 oncologists and mid-level professionals. The number of lives under value-based contracts remained stable at approximately 1.9 million. The company also reported a reduction in selling, general, and administrative expenses by 5% year-over-year, reflecting ongoing cost management initiatives. Despite these efforts, total operating expenses increased to $144.6 million for the quarter, up from $113.8 million in the prior year, largely due to rising direct costs associated with patient services and dispensary operations.
Strategically, The Oncology Institute entered into a Research Services Agreement with Helios CR, Inc. in March 2025, which shifted the management of its clinical trials segment to Helios under a profit-sharing arrangement. This transition resulted in a $2.4 million write-off of net assets related to the clinical trials segment for the nine months ended September 30, 2025. Additionally, the company successfully raised approximately $16.5 million through a private placement in March 2025 and generated $11.8 million from its at-the-market offering program during the third quarter.
The company’s balance sheet as of September 30, 2025, showed total assets of $163.6 million, down from $172.7 million at the end of 2024. Cash and cash equivalents decreased to $27.7 million, while total liabilities increased to $175.9 million, primarily due to higher accounts payable and long-term debt. The company’s accumulated deficit also grew to $263.9 million. Looking ahead, The Oncology Institute expressed confidence in its liquidity, stating that it expects to have sufficient capital to fund operations for at least the next year, despite the ongoing challenges in the healthcare market.
About Oncology Institute, Inc.
The Oncology Institute, Inc. specializes in outpatient oncology care, offering fee-for-service and value-based contracts across multiple states. It operates clinics providing medical oncology, radiation therapy, pharmacy services, and clinical trials, primarily serving adult and senior populations. The company emphasizes evidence-based, cost-efficient care aligned with clinical guidelines, partnering with payors to manage oncology populations and improve outcomes while reducing costs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.